Clinical performance of a low cost near infrared sensor for continuous glucose monitoring applied with subcutaneous microdialysis

Mohammadi, L. Ben; Klotzbuecher, Thomas; Sigloch, S.; Welzel, K.; Goeddel, M.; Pieber, Thomas R.; Schaupp, Lukas

doi:10.1007/s10544-015-9983-4

Cited by 14 publications

(7 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A minimally invasive chip-based NIR CGM sensor using microdialysis of ISF has been suggested by Mohammadi et al The sensor has been used in two in vivo trials, the first on 10 DM1 patients for 30 hours (77), and the second one with six subjects for 12 hours (78). The glucose concentration range was approximately 60-350 mg/dl.…”

Section: Research Statusmentioning

confidence: 99%

A review of optical methods for continuous glucose monitoring

Jernelv

Mileńko

Fuglerud

et al. 2018

Applied Spectroscopy Reviews

112

View full text Add to dashboard Cite

Frequent glucose monitoring is a fundamental part of diabetes management, and good glucose control is important for long-term health outcomes. New types of electrochemical sensors that allow for continuous glucose monitoring (CGM) have become an important tool for diabetes management, although they still have drawbacks such as short lifetime and a need for frequent calibration. Other technologies are still being researched for CGM, in an attempt to replace the electrochemical sensors. Optical methods have several advantages for CGM, including potentially long sensor lifetimes and short measurement times, and many developments have been made over the last decades. This paper will review optical measurement methods for CGM, their challenges, and the current research status. The different methods will be compared, and the future prospects for optical methods will be discussed.

show abstract

Section: Research Statusmentioning

confidence: 99%

A review of optical methods for continuous glucose monitoring

Jernelv

Mileńko

Fuglerud

et al. 2018

Applied Spectroscopy Reviews

112

View full text Add to dashboard Cite

show abstract

“…Within continuous glucose monitoring devices, we defined a total of 7 groups based on the similarity of the devices and the manufacturer: Medtronic devices, 21 - 24 Eversense (Senseonics), 21 , 25 - 28 Dexcom devices, 21 , 23 , 29 - 36 Glucotrack (Integrity Applications), 37 , 38 an infrared sensor for subcutaneous microdialysis (Fraunhofer ICT-IMM), 39 subcutaneous monitoring systems (Biovotion), 40 and NovioSense glucose sensor (NovioSense). 41 All of the mentioned devices measured glucose levels on interstitial tissue or tears (see Figure 2 and Supplemental Table 1 ).…”

Section: Resultsmentioning

confidence: 99%

“… 20 , 57 In this study, we opted to use MARD, an indicator that evaluates variability between measurements, with a stringent cutoff point of 10% and we found that the only device that met the criteria were TensorTip Combo Glucometer 48 and the Opto-fluidic near-infrared (NIR) continuous glucose monitor. 39 Nevertheless, each of the devices had only 1 validation study, suggesting a need to conduct more studies to compare and contrast the results as the MARD is usually very variable.…”

Section: Discussionmentioning

confidence: 99%

Technologies for Diabetes Self-Monitoring: A Scoping Review and Assessment Using the REASSURED Criteria

Zafra-Tanaka

Beran

Vetter

et al. 2021

J Diabetes Sci Technol

View full text Add to dashboard Cite

Background: Self-management is an important pillar for diabetes control and to achieve it, glucose self-monitoring devices are needed. Currently, there exist several different devices in the market and many others are being developed. However, whether these devices are suitable to be used in resource constrained settings is yet to be evaluated. Aims: To assess existing glucose monitoring tools and also those in development against the REASSURED which have been previously used to evaluate diagnostic tools for communicable diseases. Methods: We conducted a scoping review by searching PubMed for peer-review articles published in either English, Spanish or Portuguese in the last 5 years. We selected papers including information about devices used for self-monitoring and tested on humans with diabetes; then, the REASSURED criteria were used to assess them. Results: We found a total of 7 continuous glucose monitoring device groups, 6 non-continuous, and 6 devices in development. Accuracy varied between devices and most of them were either invasive or minimally invasive. Little to no evidence is published around robustness, affordability and delivery to those in need. However, when reviewing publicly available prices, none of the devices would be affordable for people living in low- and middle-income countries. Conclusions: Available devices cannot be considered adapted for use in self-monitoring in resource constraints settings. Further studies should aim to develop less-invasive devices that do not require a large set of components. Additionally, we suggest some improvement in the REASSURED criteria such as the inclusion of patient-important outcomes to increase its appropriateness to assess non-communicable diseases devices.

show abstract

“…In 2015, they followed up with a demonstration for establishing a non-invasive model according to Beer-Lambert's law rather than using chemometrics [95]. In the same year, Mohammadi et al reported a minimally invasive NIR CGM system using microdialysis of ISF and tested on six T1D patients [70]. molecules, such as lactate and urea (Figure 5D) [87].…”

Section: Near-infrared (Nir) Spectroscopymentioning

confidence: 99%